文献速递间质性肺疾病

血清高迁移率族蛋白B1与特发性肺纤维化急性加重的发生及严重程度相关

Serum high-mobility group box 1 is associated with the onset and severity of acute exacerbation of idiopathic pulmonary fibrosis.
PubMed 文献 · Respirology · 2019-07-03

本研究纳入76例稳定期IPF、17例AE-IPF、37例COPD患者和74例健康对照,比较血清HMGB1水平并评估其与AE发生及预后的关联。结果显示AE-IPF患者HMGB1最高,稳定期IPF高于健康对照,较高HMGB1与稳定期IPF更早发生AE及AE-IPF更短生存相关。

要点

  • AE-IPF患者血清HMGB1水平显著高于稳定期IPF和健康对照。
  • 稳定期IPF患者HMGB1较高者急性加重发生更早。
  • AE-IPF患者HMGB1较高者生存期更短。

核心结论

  • 较高血清HMGB1预测稳定期IPF患者更早发生急性加重及AE-IPF患者更短生存。

研究设计与样本

  • 纳入76例稳定期IPF、17例AE-IPF、37例COPD患者和74例健康对照,比较四组血清HMGB1水平。
  • 在稳定期IPF中评估HMGB1与AE发生及预后的关联,在AE-IPF中评估HMGB1的预后价值。

主要发现

  • 稳定期IPF患者血清HMGB1显著高于健康对照(3.42 ± 2.69 vs 健康对照,具体数值原文未单独列出)。
  • AE-IPF患者HMGB1为19.20 ± 16.76 ng/mL,高于稳定期IPF的6.26 ± 5.27 ng/mL和健康对照的3.42 ± 2.69 ng/mL。
  • 稳定期IPF与COPD患者间血清HMGB1水平无显著差异。
  • 较高HMGB1与稳定期IPF更早发生AE相关(P = 0.030)。
  • 较高HMGB1与AE-IPF更短生存相关(P = 0.001)。

临床怎么用

  • 血清HMGB1或可作为稳定期IPF患者急性加重风险的提示指标。
  • 在AE-IPF患者中,HMGB1水平或有助于预后判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: High-mobility group box 1 (HMGB1) is a known mediator of acute lung injury through the acceleration of pro-inflammatory -signalling. Previous studies showed that HMGB1 is increased in the lung and circulation of patients with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF). This study investigated the predictive value of circulatory HMGB1 for disease progression and prognosis of IPF in the stable phase and AE phase. METHODS: In total, 76 patients with stable IPF, 17 patients with AE-IPF, 37 patients with chronic obstructive pulmonary disease (COPD) and 74 healthy controls were included. Serum HMGB1 levels were compared among the four groups and the associations of HMGB1 levels with the onset of AE and prognosis were evaluated in patients with stable IPF. The prognostic value of HMGB1 was determined in AE-IPF. RESULTS: Serum HMGB1 levels in patients with stable IPF were significantly higher than those in healthy controls, and in patients with AE-IPF they were even higher than the levels in either of these groups (6.26 ± 5.27, 3.42 ± 2.69 and 19.20 ± 16.76 ng/mL, respectively). There was no significant difference in serum HMGB1 levels between stable IPF patients and COPD patients. Higher levels of HMGB1 were associated with earlier onset of AE in stable IPF patients and with shorter survival in AE-IPF patients (P = 0.030 and 0.001, respectively). CONCLUSION: Higher levels of serum HMGB1 predict earlier onset of AE in stable IPF patients and shorter survival in AE-IPF patients, indicating that HMGB1 is associated with acute deterioration of the disease.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Yamaguchi K, Iwamoto H, Sakamoto S, et al. Serum high-mobility group box 1 is associated with the onset and severity of acute exacerbation of idiopathic pulmonary fibrosis. Respirology. 2019. PMID: 31270920. doi:10.1111/resp.13634

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。